IFM Investors Pty Ltd Has $23.50 Million Stock Holdings in Stryker Corporation $SYK

IFM Investors Pty Ltd grew its holdings in Stryker Corporation (NYSE:SYK) by 4.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,506 shares of the medical technology company’s stock after acquiring an additional 2,762 shares during the period. IFM Investors Pty Ltd’s holdings in Stryker were worth $23,496,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of SYK. Mitchell Mcleod Pugh & Williams Inc. lifted its stake in shares of Stryker by 1.2% in the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock valued at $880,000 after purchasing an additional 31 shares during the last quarter. Key Financial Inc boosted its holdings in Stryker by 8.2% in the first quarter. Key Financial Inc now owns 856 shares of the medical technology company’s stock worth $281,000 after purchasing an additional 65 shares in the last quarter. iA Global Asset Management Inc. increased its position in Stryker by 15,336.6% during the first quarter. iA Global Asset Management Inc. now owns 6,329 shares of the medical technology company’s stock worth $2,080,000 after buying an additional 6,288 shares during the last quarter. MQS Management LLC raised its holdings in Stryker by 22.4% during the first quarter. MQS Management LLC now owns 2,943 shares of the medical technology company’s stock valued at $967,000 after buying an additional 538 shares in the last quarter. Finally, Mayflower Financial Advisors LLC raised its holdings in Stryker by 13.0% during the first quarter. Mayflower Financial Advisors LLC now owns 3,758 shares of the medical technology company’s stock valued at $1,235,000 after buying an additional 433 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. UBS Group decreased their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Citigroup cut their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Jefferies Financial Group restated a “buy” rating and issued a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. JPMorgan Chase & Co. decreased their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $395.33.

Stryker Trading Down 4.8%

Shares of NYSE:SYK opened at $314.81 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock’s 50-day moving average is $310.38 and its 200-day moving average is $339.43. The company has a market cap of $120.69 billion, a P/E ratio of 36.44, a P/E/G ratio of 2.12 and a beta of 0.78. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period in the prior year, the firm posted $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Insider Activity

In related news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.